The city of Baltimore, Maryland, currently has 8 active clinical trials seeking participants for Parkinson's Disease research studies.
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
NCT05539196
Recruiting
This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.
Gender:
All
Ages:
Between 30 years and 99 years
Trial Updated:
05/30/2024
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Movement Disorders, Neurology, Parkinsons Disease
Register for Updates
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
NCT05819359
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
05/29/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland +2 locations
Conditions: Parkinson's Disease
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Parkinson's Disease
Register for Updates
Effects of RAS on Gait in PD Patients With DBS
NCT05763732
Recruiting
Participants will be asked to walk along with the metronome beats (RAS) during the participants' stimulation state (ON or OFF) for four minutes for each state. The researcher will collect the gait parameters (cadence, velocity, and stride length) of patients before, during, and after RAS in both DBS ON and OFF states. Using MDS-UPDRS, participants' gait patterns will be collected before and after RAS while both DBS is ON and OFF. Electrophysiological activity (local field potentials, LFPs) wil... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
04/09/2024
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Parkinson Disease
Register for Updates
Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation
NCT03074812
Recruiting
This study evaluates the effect of transcranial direct current stimulation (tDCS) on non-motor symptoms of Parkinson's disease, including depression and cognitive symptoms. Participants are randomized to receive active or sham tDCS for 30 minutes over 10 treatment sessions.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
03/20/2024
Locations: Johns Hopkins Hospital / Johns Hopkins University, Baltimore, Maryland
Conditions: Idiopathic Parkinson's Disease, Parkinson Disease, Depression
Register for Updates
Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
NCT05636852
Recruiting
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study will determine if a lower dose (5 millicuries) would suffice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Parkinson Disease, Movement Disorders
Register for Updates
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
All
Ages:
30 years and above
Trial Updated:
12/13/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Parkinson Disease
Register for Updates
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
NCT05824728
Recruiting
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and u... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
10/11/2023
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Parkinson Disease Psychosis
Register for Updates